Pennsylvania Governor Josh Shapiro is set to sign legislation aimed at curbing the misuse of xylazine, a potent animal tranquilizer found in illicit drugs. This move comes in response to the alarming rise in human overdose deaths linked to xylazine-laced substances.
While the tranquilizer will remain legal for veterinary use, its misuse in drugs like fentanyl and heroin has led to serious health risks and fatalities.
The bill, which has garnered approval from both the state House of Representatives and the Senate, classifies xylazine as a “schedule III” drug under Pennsylvania’s controlled substance law. This formalizes a previous order by Governor Shapiro, aligning Pennsylvania with other states that have moved to restrict access to xylazine.
Primarily used by veterinarians to sedate and treat animals, xylazine has found its way into illicit drug supplies, where it is often mixed with opioids for its sedative effects. This misuse has resulted in thousands of drug-related deaths across the United States, prompting federal authorities to designate xylazine-laced fentanyl as an “emerging threat.”
The legislation imposes penalties, including imprisonment of up to five years, for the illicit use of schedule III drugs. Additionally, it mandates safe storage practices for professionals to prevent theft or unauthorized access to xylazine.
Xylazine misuse in humans can lead to dangerous drops in breathing and heart rates, as well as severe injection-related injuries like open sores and infections, sometimes requiring amputation. Federal efforts are underway to bolster testing, treatment, and interception measures to combat the illegal trafficking of xylazine-laced drugs.